Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 59,854 shares at $27.95 ($1.7M) on 2024-10-08, disclosed to the SEC on 2024-10-10.
Scheduled sale ($1.7M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.95 | 13,167 | $368K | 21.9% |
| 2 | $27.95 | 13,167 | $368K | 21.9% |
| 3 | $28.51 | 100 | $3K | 0.2% |
| 4 | $28.07 | 13,880 | $390K | 23.2% |
| 5 | $28.07 | 13,880 | $390K | 23.2% |
| 6 | $28.53 | 2,830 |
| $81K |
| 4.8% |
| 7 | $28.53 | 2,830 | $81K | 4.8% |
| Total | $28.06 avg | 59,854 | $1.7M | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |